Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 3Cytokine Release Syndrome 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 61Rituximab 50fludarabine 34Prednisone 33Doxorubicin 28Biopsy 26Vincristine 25Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 16Lenalidomide 16obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × siltuximab × 1 year × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡